These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 32214015)
1. Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. Markovic M; Zur M; Fine-Shamir N; Haimov E; González-Álvarez I; Dahan A Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32214015 [TBL] [Abstract][Full Text] [Related]
2. The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract. Zur M; Cohen N; Agbaria R; Dahan A Int J Pharm; 2015 Jul; 489(1-2):304-10. PubMed ID: 25957705 [TBL] [Abstract][Full Text] [Related]
3. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Zur M; Gasparini M; Wolk O; Amidon GL; Dahan A Mol Pharm; 2014 May; 11(5):1707-14. PubMed ID: 24735251 [TBL] [Abstract][Full Text] [Related]
4. Understanding B Shekhawat P; B Pokharkar V Acta Pharm Sin B; 2017 May; 7(3):260-280. PubMed ID: 28540164 [TBL] [Abstract][Full Text] [Related]
5. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation. Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569 [TBL] [Abstract][Full Text] [Related]
6. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Markovic M; Zur M; Ragatsky I; Cvijić S; Dahan A Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33276565 [TBL] [Abstract][Full Text] [Related]
7. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482 [TBL] [Abstract][Full Text] [Related]
8. pH-Dependent Solubility and Dissolution Behavior of Carvedilol--Case Example of a Weakly Basic BCS Class II Drug. Hamed R; Awadallah A; Sunoqrot S; Tarawneh O; Nazzal S; AlBaraghthi T; Al Sayyad J; Abbas A AAPS PharmSciTech; 2016 Apr; 17(2):418-26. PubMed ID: 26202065 [TBL] [Abstract][Full Text] [Related]
9. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251 [TBL] [Abstract][Full Text] [Related]
10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
11. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. Corrigan OI Adv Exp Med Biol; 1997; 423():111-28. PubMed ID: 9269487 [TBL] [Abstract][Full Text] [Related]
12. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. Zur M; Hanson AS; Dahan A Eur J Pharm Sci; 2014 Sep; 61():11-7. PubMed ID: 24262076 [TBL] [Abstract][Full Text] [Related]
13. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer. Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451 [TBL] [Abstract][Full Text] [Related]
14. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay. Fine-Shamir N; Dahan A Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762 [TBL] [Abstract][Full Text] [Related]
15. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels. Beig A; Miller JM; Lindley D; Dahan A Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848 [TBL] [Abstract][Full Text] [Related]
16. Ethanol-based solubility-enabling oral drug formulation development: Accounting for the solubility-permeability interplay. Fine-Shamir N; Dahan A Int J Pharm; 2024 Mar; 653():123893. PubMed ID: 38346600 [TBL] [Abstract][Full Text] [Related]
17. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504 [TBL] [Abstract][Full Text] [Related]
18. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047 [TBL] [Abstract][Full Text] [Related]
19. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
20. Physicochemical profiling (solubility, permeability and charge state). Avdeef A Curr Top Med Chem; 2001 Sep; 1(4):277-351. PubMed ID: 11899112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]